Maravai Lifesciences Aktie

Declining Stock and Solid Fundamentals: Is The Market Wrong About Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)? Simply Wall St Mon, August 29, 2022 at 7:47 PM In this article: MRVI -0.29% With its stock down 35% over the past three months, it is easy to disregard Maravai LifeSciences Holdings (NASDAQ:MRVI). However, a closer look at its sound financials might cause you to think again. Given that fundamentals usually drive long-term market outcomes, the company is worth looking at. In this article, we decided to focus on Maravai LifeSciences Holdings' ROE. Return on equity or ROE is an important factor to be considered by a shareholder because it tells them how effectively their capital is being reinvested. Put another way, it reveals the company's success at turning shareholder investments into profits. Check out our latest analysis for Maravai LifeSciences Holdings How Is ROE Calculated? ROE can be calculated by using the formula: Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity So, based on the above formula, the ROE for Maravai LifeSciences Holdings is: 73% = US$563m ÷ US$774m (Based on the trailing twelve months to June 2022). The 'return' is the income the business earned over the last year. One way to conceptualize this is that for each $1 of shareholders' capital it has, the company made $0.73 in profit. What Is The Relationship Between ROE And Earnings Growth? So far, we've learned that ROE is a measure of a company's profitability. We now need to evaluate how much profit the company reinvests or "retains" for future growth which then gives us an idea about the growth potential of the company. Assuming everything else remains unchanged, the higher the ROE and profit retention, the higher the growth rate of a company compared to companies that don't necessarily bear these characteristics. Maravai LifeSciences Holdings' Earnings Growth And 73% ROE Firstly, we acknowledge that Maravai LifeSciences Holdings has a significantly high ROE. Second, a comparison with the average ROE reported by the industry of 17% also doesn't go unnoticed by us. Under the circumstances, Maravai LifeSciences Holdings' considerable five year net income growth of 65% was to be expected. Next, on comparing with the industry net income growth, we found that Maravai LifeSciences Holdings' growth is quite high when compared to the industry average growth of 35% in the same period, which is great to see. past-earnings-growth past-earnings-growth The basis for attaching value to a company is, to a great extent, tied to its earnings growth. What investors need to determine next is if the expected earnings growth, or the lack of it, is already built into the share price. Doing so will help them establish if the stock's future looks promising or ominous. Is Maravai LifeSciences Holdings fairly valued compared to other companies? These 3 valuation measures might help you decide. Is Maravai LifeSciences Holdings Making Efficient Use Of Its Profits? Given that Maravai LifeSciences Holdings doesn't pay any dividend to its shareholders, we infer that the company has been reinvesting all of its profits to grow its business. Conclusion On the whole, we feel that Maravai LifeSciences Holdings' performance has been quite good. In particular, it's great to see that the company is investing heavily into its business and along with a high rate of return, that has resulted in a sizeable growth in its earnings. Having said that, on studying current analyst estimates, we were concerned to see that while the company has grown its earnings in the past, analysts expect its earnings to shrink in the future

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. Maravai LifeSciences Holdings, Inc. was incorporated in 2020 and is headquartered in San Diego, California.

Maravai LifeSciences Holdings, Inc. (MRVI) NasdaqGS - NasdaqGS Real Time Price. Currency in USD Add to watchlist Quote Lookup 26.00-0.52 (-1.96%)